title: Bladder and erectile dysfunctions in the Type 2 diabetic Goto-Kakizaki rat.
abstract: Despite the fact that urogenito-sexual complications significantly impact the quality of life of diabetic patients, a robust in vivo experimental model is lacking. Bladder and erectile function in the Type 2 diabetic Goto-Kakizaki (GK) rat and responses to standard-of-care treatments for each disorder have been assessed. GK rats (n = 25, 18-wk-old, GK/Par colony) and age-matched Wistar rats (n = 23), characterized for their metabolic parameters, were used. Bladder function was assessed by cystometry in conscious rats treated by intravenous solifenacin (1 mg/kg). Subsequently, erectile function was assessed under anesthesia following electrical stimulation of the cavernous nerve in presence of intravenous sildenafil (0.3 mg/kg). GK rats displayed detrusor overactivity with a significant increase in frequency/amplitude of nonvoiding contractions during the filling phase, together with an increase in bladder capacity, intercontraction interval, voided volume, and maximal pressure of voiding contraction. Solifenacin significantly decreased parameters characterizing voiding contractions without modifying voiding efficiency. Erectile function in GK rats was markedly impaired and remained so after sildenafil treatment despite a significant improvement. GK rats display both bladder and erectile dysfunctions and respond at least partially to standard-of-care treatments for each disorder, thus representing a suitable model to investigate the pathophysiology and assess the efficacy of new therapeutic agents for Type 2 diabetes-associated bladder and erectile complications.
authors.affiliation: Pelvipharm, Montigny-le-Bretonneux, France;
authors.forename: Stephanie
authors.initials: S
authors.lastname: Oger-Roussel
authors.forename: Delphine
authors.initials: D
authors.lastname: Behr-Roussel
authors.forename: Stephanie
authors.initials: S
authors.lastname: Caisey
authors.forename: Micheline
authors.initials: M
authors.lastname: Kergoat
authors.forename: Christine
authors.initials: C
authors.lastname: Charon
authors.forename: Annick
authors.initials: A
authors.lastname: Audet
authors.forename: Jacques
authors.initials: J
authors.lastname: Bernabé
authors.forename: Laurent
authors.initials: L
authors.lastname: Alexandre
authors.forename: Francois
authors.initials: F
authors.lastname: Giuliano
mesh_terms: D000818:Animals; D048909:Diabetes Complications / Q000503:physiopathology*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000503:physiopathology; D007172:Erectile Dysfunction / Q000209:etiology*; D008297:Male; D010410:Penile Erection / Q000187:drug effects; D010879:Piperazines / Q000494:pharmacology; D011687:Purines / Q000494:pharmacology; D011812:Quinuclidines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D000068677:Sildenafil Citrate; D000069464:Solifenacin Succinate; D013450:Sulfones / Q000494:pharmacology; D044005:Tetrahydroisoquinolines / Q000494:pharmacology; D001743:Urinary Bladder / Q000502:physiology; D001745:Urinary Bladder Diseases / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D014554:Urination / Q000187:drug effects / Q000502:physiology; D064804:Urological Agents / Q000494:pharmacology; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D010879:Piperazines; D011687:Purines; D011812:Quinuclidines; D013450:Sulfones; D044005:Tetrahydroisoquinolines; D064804:Urological Agents; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate; D000069464:Solifenacin Succinate
keywords: antimuscarinic; phosphodiesterase type 5 inhibitor; sexual dysfunction; urology